This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Body, J.-J. Articles by Hodsman, A. B. Search for Related Content PubMed PubMed Citation Articles by Body, J.-J. Articles by Hodsman, A. B.

A Randomized Double-Blind Trial to Compare the Efficacy of Teriparatide [Recombinant Human Parathyroid Hormone (1–34)] with Alendronate in Postmenopausal Women with Osteoporosis

Department of Medicine (J.-J.B.), Institut J. Bordet, Université Libre de Bruxelles, 1000 Brussels, Belgium; Lilly Research Laboratories (G.A.G., W.H.S., P.M.K.), Eli Lilly and Co., Indianapolis, Indiana 46285; Colorado Center for Bone Research (P.D.M.), Lakewood, Colorado 80227; Centre Hospitalier Universitaire Brugmann (A.Pe.), Rheumatology Clinic, 1020 Brussels, Belgium; (R.K.D.), Anaheim, California 92801; Department of Nephrology and Mineral Metabolism (R.C.-R.), Instituto Nacional de Ciencias Médicas Y Nutrición Salvador Zubiran, 14000 Mexico DF, Mexico; Department of Medicine (A.Pa.), Hamilton Health Sciences, McMaster University, Hamilton, L8N 3Z5 Ontario, Canada; Department of Obstetrics and Gynecology (D.C.C.), Royal Alexandra Hospital, University of Alberta, Edmonton, T5H 3V9 Alberta, Canada; and Department of Medicine (A.B.H.), St. Joseph’s Health Care Center London and Lawson Health Research Institute, University of Western Ontario, London, N6A 4V2 Ontario, Canada

Address all correspondence to: Prof. J. J. Body, Institut J. Bordet, 1, rue Héger-Bordet, 1000 Bruxelles, Belgium. E-mail: jj.body{at}bordet.be. Address requests for reprints to: Gregory A. Gaich, M.D., Lilly Research Laboratories, Eli Lilly and Co., Lilly Corporate Center, Indianapolis, Indiana 46285.

Abstract

Teriparatide (rDNA origin) injection [recombinant human PTH (1–34)] stimulates bone formation, increases bone mineral density (BMD), and restores bone architecture and integrity. In contrast, bisphosphonates reduce bone resorption and increase BMD. We compared the effects of teriparatide and alendronate sodium on BMD, nonvertebral fracture incidence, and bone turnover in 146 postmenopausal women with osteoporosis. Women were randomized to either once-daily sc injections of teriparatide 40 µg plus oral placebo (n = 73) or oral alendronate 10 mg plus placebo injection (n = 73). Median duration of treatment was 14 months. At 3 months, teriparatide increased lumbar spine BMD significantly more than did alendronate (P < 0.001). Lumbar spine-BMD increased by 12.2% in the teriparatide group and 5.6% in the alendronate group (P < 0.001 teriparatide vs. alendronate). Teriparatide increased femoral neck BMD and total body bone mineral significantly more than did alendronate, but BMD at the one third distal radius decreased, compared with alendronate (P 0.05). Nonvertebral fracture incidence was significantly lower in the teriparatide group than in the alendronate group (P < 0.05). Both treatments were well tolerated despite transient mild asymptomatic hypercalcemia with teriparatide treatment. In conclusion, teriparatide, a bone formation agent, increased BMD at most sites and decreased nonvertebral fractures more than alendronate.

This article has been cited by other articles:

				A.E. Kearns and D.F. Kallmes Osteoporosis Primer for the Vertebroplasty Practitioner: Expanding the Focus Beyond Needles and Cement AJNR Am. J. Neuroradiol., November 1, 2008; 29(10): 1816 - 1822. [Abstract] [Full Text] [PDF]

				A. Qaseem, V. Snow, P. Shekelle, R. Hopkins Jr., M. A. Forciea, D. K. Owens, and for the Clinical Efficacy Assessment Subcommittee Pharmacologic Treatment of Low Bone Density or Osteoporosis to Prevent Fractures: A Clinical Practice Guideline from the American College of Physicians Ann Intern Med, September 16, 2008; 149(6): 404 - 415. [Abstract] [Full Text] [PDF]

				P. G Clay, L. E Voss, C. Williams, and E. C Daume Valid Treatment Options for Osteoporosis and Osteopenia in HIV-Infected Persons Ann. Pharmacother., May 1, 2008; 42(5): 670 - 679. [Abstract] [Full Text] [PDF]

				J. Stroup, M. P. Kane, and A. M. Abu-Baker Teriparatide in the treatment of osteoporosis Am. J. Health Syst. Pharm., March 15, 2008; 65(6): 532 - 539. [Abstract] [Full Text] [PDF]

				C. MacLean, S. Newberry, M. Maglione, M. McMahon, V. Ranganath, M. Suttorp, W. Mojica, M. Timmer, A. Alexander, M. McNamara, et al. Systematic Review: Comparative Effectiveness of Treatments to Prevent Fractures in Men and Women with Low Bone Density or Osteoporosis Ann Intern Med, February 5, 2008; 148(3): 197 - 213. [Abstract] [Full Text] [PDF]

				E. C. Hsiao, B. M. Boudignon, W. C. Chang, M. Bencsik, J. Peng, T. D. Nguyen, C. Manalac, B. P. Halloran, B. R. Conklin, and R. A. Nissenson From the Cover: Osteoblast expression of an engineered Gs-coupled receptor dramatically increases bone mass PNAS, January 29, 2008; 105(4): 1209 - 1214. [Abstract] [Full Text] [PDF]

				K. G. Saag, E. Shane, S. Boonen, F. Marin, D. W. Donley, K. A. Taylor, G. P. Dalsky, and R. Marcus Teriparatide or Alendronate in Glucocorticoid-Induced Osteoporosis N. Engl. J. Med., November 15, 2007; 357(20): 2028 - 2039. [Abstract] [Full Text] [PDF]

				P. D. Miller, J. P. Bilezikian, M. Diaz-Curiel, P. Chen, F. Marin, J. H. Krege, M. Wong, and R. Marcus Occurrence of Hypercalciuria in Patients with Osteoporosis Treated with Teriparatide J. Clin. Endocrinol. Metab., September 1, 2007; 92(9): 3535 - 3541. [Abstract] [Full Text] [PDF]

				H. I.J. Wildschut, T.J. Peters, and C. P. Weiner Screening in women's health, with emphasis on fetal Down's syndrome, breast cancer and osteoporosis Hum. Reprod. Update, September 1, 2006; 12(5): 499 - 512. [Abstract] [Full Text] [PDF]

				J. S. Finkelstein, B. Z. Leder, S.-A. M. Burnett, J. J. Wyland, H. Lee, A. V. de la Paz, K. Gibson, and R. M. Neer Effects of Teriparatide, Alendronate, or Both on Bone Turnover in Osteoporotic Men J. Clin. Endocrinol. Metab., August 1, 2006; 91(8): 2882 - 2887. [Abstract] [Full Text] [PDF]

				A. Cranney, A. Papaioannou, N. Zytaruk, D. Hanley, J. Adachi, D. Goltzman, T. Murray, A. Hodsman, and for the Clinical Guidelines Committee of Osteoporo Parathyroid hormone for the treatment of osteoporosis: a systematic review. Can. Med. Assoc. J., July 4, 2006; 175(1): 52 - 59. [Abstract] [Full Text] [PDF]

				H. Liu, K. Michaud, S. Nayak, D. B. Karpf, D. K. Owens, and A. M. Garber The Cost-effectiveness of Therapy With Teriparatide and Alendronate in Women With Severe Osteoporosis. Arch Intern Med, June 12, 2006; 166(11): 1209 - 1217. [Abstract] [Full Text] [PDF]

				B. T. Summey and G. Yosipovitch Glucocorticoid-Induced Bone Loss in Dermatologic Patients: An Update Arch Dermatol, January 1, 2006; 142(1): 82 - 90. [Abstract] [Full Text] [PDF]

				M. R. McClung, J. San Martin, P. D. Miller, R. Civitelli, F. Bandeira, M. Omizo, D. W. Donley, G. P. Dalsky, and E. F. Eriksen Opposite Bone Remodeling Effects of Teriparatide and Alendronate in Increasing Bone Mass Arch Intern Med, August 8, 2005; 165(15): 1762 - 1768. [Abstract] [Full Text] [PDF]

				A. B. Hodsman, D. C. Bauer, D. W. Dempster, L. Dian, D. A. Hanley, S. T. Harris, D. L. Kendler, M. R. McClung, P. D. Miller, W. P. Olszynski, et al. Parathyroid Hormone and Teriparatide for the Treatment of Osteoporosis: A Review of the Evidence and Suggested Guidelines for Its Use Endocr. Rev., August 1, 2005; 26(5): 688 - 703. [Abstract] [Full Text] [PDF]

				K. A Cappuzzo and J. C Delafuente Teriparatide for Severe Osteoporosis Ann. Pharmacother., February 1, 2004; 38(2): 294 - 302. [Abstract] [Full Text] [PDF]

				S. A. Brown and J. L. Sharpless Osteoporosis: An Under-appreciated Complication of Diabetes Clin. Diabetes, January 1, 2004; 22(1): 10 - 20. [Abstract] [Full Text] [PDF]

				J.-S. Shao, S.-L. Cheng, N. Charlton-Kachigian, A. P. Loewy, and D. A. Towler Teriparatide (Human Parathyroid Hormone (1-34)) Inhibits Osteogenic Vascular Calcification in Diabetic Low Density Lipoprotein Receptor-deficient Mice J. Biol. Chem., December 12, 2003; 278(50): 50195 - 50202. [Abstract] [Full Text] [PDF]

				A. B. Hodsman, D. A. Hanley, M. P. Ettinger, M. A. Bolognese, J. Fox, A. J. Metcalfe, and R. Lindsay Efficacy and Safety of Human Parathyroid Hormone-(1-84) in Increasing Bone Mineral Density in Postmenopausal Osteoporosis J. Clin. Endocrinol. Metab., November 1, 2003; 88(11): 5212 - 5220. [Abstract] [Full Text] [PDF]

				J. S. Finkelstein, A. Hayes, J. L. Hunzelman, J. J. Wyland, H. Lee, and R. M. Neer The Effects of Parathyroid Hormone, Alendronate, or Both in Men with Osteoporosis N. Engl. J. Med., September 25, 2003; 349(13): 1216 - 1226. [Abstract] [Full Text] [PDF]

				N. B. Watts Efficacy of Teriparatide and Alendronate on Nonvertebral Fractures J. Clin. Endocrinol. Metab., March 1, 2003; 88(3): 1402 - 1403. [Full Text]

				Injectable Parathyroid Hormone: A Powerful New Agent Against Osteoporosis Journal Watch Women's Health, January 8, 2003; 2003(108): 4 - 4. [Full Text]